Immunic to Participate in Industry and Investor Conferences in November
Immunic, Inc.(Nasdaq: IMUX),a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following industry and investor conferences in November: — November 3-5:BIO-Europe. Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, Hella Kohlhof, Ph.D., Chief Scientific Officer and Jessica Breu, Vice President […]